OTCM
STEK
, Last price
USD
Name
Stemtech Corp
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
215.88%
Rev. 5Y
-8.09%
Div Yld LY
—
Div Yld TTM
—
Revenues
3m
-43.08%
Net income
-4m
L+7.35%
CFO
-484k
L-19.56%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Stemtech Corporation is a pioneering company specializing in stem cell nutrition. It formulates scientifically-backed products designed to optimize the body's intrinsic stem cell physiology. With a market presence spanning the Americas, Latin America, and Asia, its offerings are engineered to bolster the natural functions of the body's stem cells. These solutions achieve this by stimulating the release of more stem cells, facilitating their efficient circulation through the bloodstream, and guiding their migration into various tissues. This process enables the stem cells to perform their continuous regenerative and repair tasks, crucial for maintaining optimal health and vitality. The company's comprehensive portfolio of dietary supplements includes prominent brands such as RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze. Stemtech Corporation's operations are headquartered in Miramar, Florida.
Key people
Gustavo Americo Folcarelli
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Corporate Secretary, Director · since 2016
Headquarters & legal address
C/O Empire Stock Transfer Inc.
1859 Whitney Mesa Drive
Henderson, NV 89014
US
1859 Whitney Mesa Drive
Henderson, NV 89014
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑08 | 2018‑08 | 2017‑08 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||